While next-generation sequencing (NGS) has enormous potential to identify genetic causes of disease, the nature of the technology means that it can also identify additional information about the individual receiving sequencing that is unrelated to the original rationale for testing. Reporting
INTRODUCTION
The introduction of next-generation sequencing (NGS) technologies into both research and clinical settings has been instrumental in the detection of many new disease-causing genes, particularly for rare diseases and cancers (Guerreiro et al., 2016; Rotunno et al., 2016; Tetzlaff et al., 2016) . NGS, which encompasses targeted gene panels and wholeexome/whole-genome sequencing, is novel in that it allows the analysis of numerous genes in a single test (Rabbani, Tekin, & Mahdieh, 2014) .
While NGS has enormous potential to identify genetic causes of disease, the nature of the technology means it can also identify additional information about the individual that is unrelated to the original rationale for sequencing, often referred to as incidental findings (Kohane, Masys, & Altman, 2006) .
The inconsistent terminology around incidental findings has caused considerable confusion (Downing, Williams, Daack-Hirsch, Driessnack, & Simon, 2013) . These findings have been referred to as unsolicited, iatrogenic, serendipitous, additional, or secondary, to name several (Botkin et al., 2015; Green et al., 2013; Matthijs et al., 2016; Tan et al., 2016; van El et al., 2013) . In particular, the term "incidental" has received criticism as it may lead patients to perceive these types of variants as trivial (Tan et al., 2016) . For this reason, we will use unsolicited findings (UF), which refers to variants in disease-causing genes that are unrelated to the original rationale for testing and that are identified inadvertently. We differentiate this from secondary findings (SF), which refers to variants in disease-causing genes that are unrelated to the original rationale for testing but that are actively sought during the analysis. This term was recently recommended by the American College of Medical Genetics and Genomics (ACMG) (Kalia et al., 2016) after their recognition that using incidental findings did not reflect their intention to actively search for these variants (Green et al., 2013) .
This concept of actively searching for SF was first proposed by the ACMG in their frequently cited recommendations in 2013 (Green et al., 2013) . In this, they described a list of causative variants in 56 genes predicted to cause 24 conditions, such as hereditary cancers and cardiac conditions, which they recommended should be actively searched for and reported in both adults and children receiving diagnostic genomic sequencing (Green et al., 2013 in 2016 and now suggests 59 genes, with an intention for 6-monthly revisions (Kalia et al., 2016) . However, other professional bodies have suggested that this kind of opportunistic screening is inappropriate and instead recommend a more targeted approach, limiting the analysis of NGS data to genes that are relevant to the phenotype of the patient (Boycott et al., 2015) .
Studies have explored patient and general public preferences regarding the return of UF Hufnagel, Martin, Cassedy, Hopkin, & Antommaria, 2016; Yu, Crouch, Jamal, Bamshad, & Tabor, 2014a) and health professionals' views about whether these findings should be reported (Lemke, Bick, Dimmock, Simpson, & Veith, 2013; Lohn et al., 2013; Yu, Harrell, Jamal, Tabor, & Bamshad, 2014b) . In 2016, a US-based study conducted a survey of US laboratories to assess their reporting practices . However, aside from a brief survey of nine European laboratories undertaken in 2013 (Hehir-Kwa et al., 2015) , no one has investigated the current practices, or perspectives, of laboratory personnel who are actually reporting results from NGS about the reporting of UF or SF outside the USA.
MATERIALS AND METHODS
This study used qualitative methods to explore the reporting practices of laboratories using NGS. Purposive sampling was used to recruit laboratory personnel who are analyzing/reporting data generated by NGS technologies, including targeted gene panels, whole-exome or wholegenome sequencing. Potential participants were identified using internet searches to identify laboratories using NGS and snowball sampling. Semistructured interviews were conducted by one member of the research team (D.V.). These interviews explored a range of different aspects relating to their use of NGS, including the types of technologies and analysis/filtering strategies used in their laboratory. Here, we report the interview components relating to the reporting of UF, how they made decisions about reporting UF, and whether they actively search for SF. Interviews were audio-recorded, transcribed verbatim, and analyzed using inductive content analysis in which content categories were derived from the data, rather than predetermined (Downe-Wamboldt, 1992; Graneheim & Lundman, 2004; Schamber, 2000) . Each transcript was coded into broad content categories. Sections of the data within the broad categories were compared and more specific subcategories were developed. All interviews were coded by D.V.; K.S. and P.B. coded a subset to confirm the coding scheme. 
RESULTS

Participant characteristics
A total of 26 interviews were conducted with 27 laboratory personnel. This included participants from 24 different laboratories in Europe (12), Canada (five), and Australasia (seven) ( Table 1) . Participants had a mean of 8.1 years (4 weeks-24 years) experience in their current role and a mean of 17.4 years (6-32 years) in the field of genetics.
Two of the participants also had training in clinical genetics. Nineteen of the 24 laboratories operate in the diagnostic context with several also including research components to their laboratory. Five of the laboratories operate purely on a research level, although they do issue reports to clinicians. At the time of the interviews, laboratories had 1-10 years of experience using NGS technologies. Twenty of the laboratories were using targeted panels, including five who were using a Mendeliome-based panel (e.g., TruSight One). Twenty-two were using exome sequencing, with or without virtual panels, and four were using whole-genome sequencing (3/4 were research laboratories). 
Reporting practices for UF
Participant 24
Other laboratories do report UF, although there is variation within this group as to which variants they would report. For some laboratories, the decision about which UF to report is based on the criterion of clinical actionability, as in whether some treatment or surveillance can be taken through the knowledge of that information.
[...] this depends on what disease it gives. For instance, we
had a variant in the Factor VIII gene which gives haemophilia.
And there we decided, because you can treat it, and it's good that you know it, there we decided to report it. So depends on […] if you can treat it or not.
Participant 10
Respondents also acknowledged it may be difficult to define the extent to which a variant might be clinically actionable. Therefore, their Notwithstanding, several of these laboratories indicated they are currently discussing whether to change their reporting practices on this point. This is because through their analysis, some carriers are being identified and there is some discomfort about their decision not to report this information. However, they raised the point that if they decide to report carrier status they would want to ensure this was done in a systematic way and that all carriers of the conditions they chose to report on would be identified. The feasibility of this is being questioned as part of these discussions.
TA B L E 1 Summary of laboratory practices
Some participants indicated that they discuss the decision about whether to report an UF or not with the referring clinician before a formal report is issued. Many of the laboratory personnel mentioned that they have team meetings, specific committees, or expert panels in which they discuss the reporting of UF (and also variants of uncertain significance). These are often multidisciplinary in nature, compris- 
Active searching for SF
While the ACMG suggests that laboratories performing sequencing should actively search for and report a predetermined list of diseasecausing variants, in addition to the variant that could explain the clinical question (Green et al., 2013; Kalia et al., 2016) , most laboratories interviewed do not actively search for these SF.
If we find it, we will report it. But we are not searching for that.
We are not doing like the American guidelines, just searching for all the actionable genes or mutations in the file. So it's just if we found it by chance or not.
Participant 25
In fact, many of the laboratories make decisions at the bioinformatics level in order to reduce the identification of UF. This is achieved by limiting their analysis to particular sets of genes relevant to the clinical question, either through gene panels or, if they are performing exome sequencing, using bioinformatics (virtual) panels. 
Participant 16
Four laboratories actively search for SF. Two of these laboratories routinely report these variants to clinicians and leave it to the discretion of the clinicians as to whether to disclose them to the family.
The other type of report we make is that we systematically analyse the variants that are pathogenic or likely pathogenic and affecting genes listed by the ACMG that are relevant for secondary findings. And so we propose to report these variants to the clinician. And after, the clinician will judge if the family is willing to know or not these variants. But the laboratory is reporting them.
Participant 18
The other two laboratories allow patients to "opt in" for this active searching to be performed and to receive these results, although one only allows this choice for competent, adult patients.
DISCUSSION
This is the first study to provide an in-depth exploration of the reporting practices of laboratories outside of the USA relating to UF and SF. Our research has identified that there is considerable variation between laboratories in the reporting of UF-while some limit their reporting to findings that are relevant to the clinical question, others will report UF to varying degrees. This corresponds with the brief survey of nine European laboratories that identified that five of the nine laboratories did not return UF (Hehir-Kwa et al., 2015) . On consideration, this variation between laboratories is not surprising given the limited specific guidance provided in the published recommendations of the countries from which we recruited participants. For example, there are no clinical guidelines in Australia that give specific recommendations about the reporting of UF. In the guidelines published by the EuroGentest network (Matthijs et al., 2016) , and the Canadian College of Medical Geneticists (CCMG) (Boycott et al., 2015) , rather than specifically recommending whether UF should be reported, they (1) recommend adopting a targeted approach to the analysis of genomic data in order to limit the identification of UF, and/or (2) suggest that laboratories should develop clear protocols about which UF they report, which must be made explicit to referring clinicians (Boycott et al., 2015; Matthijs et al., 2016 or prevention, in principle, a health-care professional should report such genetic variants," they also recommend development of a clear protocol, ultimately leaving the decision whether to report UF to the laboratory. This focus on the need to develop explicit reporting protocols, rather than providing recommendations on what they should report, implies that these professional bodies value transparency in reporting and that they trust in laboratories' abilities to make ethically sound decisions.
Within the group of participants who indicated their laboratories do report UF, different benchmarks are used between laboratories with some of our participants indicating they only report variants that are clinically actionable and others suggesting that actionability is not a requirement, provided the variant is medically relevant. In reality, the boundary between these two categories is blurred at best and is open to subjective interpretations. While actionability may be limited to situations where some form of treatment, intervention, or surveillance is possible for the individual patient, it could also encompass these aspects in relation to family members (Green et al., 2013) . This could include carrier status where the actionability associated with reporting this type of variant extends to future pregnancies, rather than just existing family members. This shows that the interpretation of what is "actionable" and "medically relevant" is partly a value-based decision.
Our findings contrast with the results of the survey conducted by O'Daniel et al. (2016) who found reporting practices relating to SF were more consistent across laboratories in the USA with all of the 21 laboratories they surveyed indicating that they return SF. In their study, the SF reported were generally those considered to be medically actionable, whether or not they were part of the original 56 genes recommended by the ACMG (Green et al., 2013) . In addition, 57%
(12/21) of laboratories in the US study said they report carrier status, 48% (10/21) report monogenic disease with childhood onset, and 57%
(12/21) report monogenic disease with adult onset . However, nine of the 21 laboratories were Clinical Sequencing Exploratory Research program laboratories, and reporting of these types of variants was more common in these research laboratories than those operating in a diagnostic capacity. One might hypothesize that in order to be in keeping with the ACMG recommendations that are explicit about the need to report these SF, the US laboratories are more likely to report SF than those we interviewed in Europe, Canada, and Australia as the European and Canadian guidelines are less explicit on this point.
Our interviews indicated that only Four of the 24 laboratories we accessed actively search for SF. Again, this is perhaps unsurprising given the positions taken by the CCMG, ESHG, and EuroGentest (Boycott et al., 2015; Matthijs et al., 2016; van El et al., 2013) . While the ESHG and EuroGentest Statements do not address active searching for disease-causing genes unrelated to the original rationale for testing specifically, their recommendation for a targeted approach to sequencing implies that they do not support it (Matthijs et al., 2016; van El et al., 2013) . The CCMG specifically stress that they " […] do not endorse the intentional clinical analysis of disease genes unrelated to the primary indication, even if the results might be medically actionable" (Boycott et al., 2015) . It is difficult to contrast this with the US-based study as it is unclear which of the laboratories they surveyed limit their reporting to UF, meaning those that are identified during the original analysis, and which laboratories specifically search for SF using a separate bioinformatics panel. However, it seems that 20/21 laboratories surveyed are, at a minimum, reporting SF from the original 56 genes on the ACMG list (Green et al., 2013) , and although not specifically stated, there is a suggestion that at least some of these laboratories are actively searching for these variants .
Authors have highlighted that there is insufficient evidence of clinical utility in testing the genes on the ACMG list (Boycott et al., 2015; Burke et al., 2013) . In addition, the removal of one of the genes from the list in the ACMG's most recent publication, based on insufficient evidence of pathogenicity, suggests that concerns about using this list for opportunistic screening are not unfounded (Kalia et al., 2016) . While the fact the ACMG intend to review and revise this list regularly is promising, it seems pertinent to stress that, according to our results, the majority of laboratories in our study are not actively searching for these SF.
We identified that most of the laboratories indicated no difference in their reporting practices for UF between children and adults; some participants indicated that their laboratories report UF in children, regardless of the age at which the condition is predicted to develop.
Interestingly, although the ESHG and EuroGentest guidelines do not
give specific recommendations regarding the reporting of UF in children (Matthijs et al., 2016; van El et al., 2013) , the CCMG recommendations specify that " […] incidental results that reveal risk for a highly penetrant condition that is medically actionable during childhood should be reported to the parents" (Boycott et al., 2015) . This is in line with guidelines for predictive testing for childhood onset conditions where testing would be deemed appropriate if it would provide medical benefit, in the form of treatment, prevention, or surveillance (Borry, Evers-Kiebooms, Cornel, Clarke, & Dierickx, 2009; British Medical Association Ethics Department, 2012) . The CCMG goes on to suggest that if variants for adult-onset conditions are identified in children, these should not be communicated unless the parents request that these UF be disclosed and "disclosure of the information could prevent serious harm to the health of a parent or family member," which should be determined on a case-by-case basis (Boycott et al., 2015) . This contrasts with guidelines for predictive testing in childhood for adult-onset conditions, as the CCMG recommendation would allow disclosure of a BRCA1 result, for example, where performing genetic testing for this in childhood would normally be refused (Borry, Goffin, Nys, & Dierickx, 2008) . This highlights the challenge associated with balancing protecting the child's future right not to know genetic information about themselves, with disclosing information that could lead to lifesaving interventions for their parents, which would also benefit the child.
It is important to consider who should be making decisions about which UF should be reported. Interviews with our participants indicated that, in most cases, decisions about which UF should be reported were not made in isolation. Rather, decisions were made on a case-by-case basis and through careful deliberation, either with fellow laboratory specialists and/or in multidisciplinary teams. Notably, the participants emphasized the expertise and critical input of clinicians, those who are members of these expert panels and also the referring specialists. These clinicians play an important role in determining the clinical relevance or actionability of UF and therefore whether they were worthy of reporting. Although most participants seemed to agree with their laboratories' reporting practices for UF, they also felt laboratories would benefit from more guidance on this issue and that more detailed recommendations to help standardize procedures were warranted. This tension between standardizing reporting practices across laboratories and wanting to discuss UF with clinicians on a case-by-case basis was also made explicit by participants' desire to report carrier status in a systematic manner. This call for more guidance implies that laboratories do not find the current reporting recom- 
CONCLUSION
In line with the recommendations by the ESHG, EuroGentest, and CCMG, many of the laboratories studied have adopted a targeted approach to their analysis, using bioinformatic/virtual panels in order to limit the overall number of variants identified, including UF (van El et al., 2013) . In addition, a small subset of laboratories has adopted a masking technique where they "hide" an ACMG-like list to avoid seeing these UF. Contrary to the ACMG recommendations (Kalia et al., 2016) , very few of the laboratories are actively searching for SF. Despite being relatively comfortable with the reporting practices of their laboratory, the calls from participants for more guidance on which UF to report suggest that current recommendations are inadequate and require further elaboration.
